Transarterial chemoembolization using degradable starch microspheres and iodized oil in the treatment of advanced hepatocellular carcinoma: Evaluation of tumor response, toxicity, and survival

Hepatobiliary and Pancreatic Diseases International

Volumn 6, Issue 3, 2007, Pages 259-266

  Kirchhoff, Timm D ^a,b   Bleck, Joerg S ^a,b   Dettmer, Arne ^a,b   Chavan, Ajay ^a,b   Rosenthal, Herbert ^a,b   Merkesdal, Sonja ^a,b   Frericks, Bernd ^a,b   Zender, Lars ^a,b   Malek, Nisar P ^a,b   Greten, Tim F ^a,b   Kubicka, Stefan ^a,b   Manns, Michael P ^a,b   Galanski, Michael ^a,b  

^a Hannover Medical School ^*

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Carcinoma; Degradable starch microspheres; Hepatocellular; Lipiodol; Survival; Transarterial chemoembolization; Tumor response

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; BILIRUBIN; CHOLINESTERASE; CISPLATIN; CREATININE; DOXORUBICIN; IODINATED POPPYSEED OIL; PETHIDINE; PROTHROMBIN; STARCH MICROSPHERE;

ABDOMINAL PAIN; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTERY DISSECTION; ARTICLE; CANCER MORTALITY; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHOLECYSTITIS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; FEMALE; FEVER; FOLLOW UP; HUMAN; LABORATORY TEST; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER NECROSIS; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; REGRESSION ANALYSIS; SIDE EFFECT; STOMACH ULCER; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR VASCULARIZATION; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CISPLATIN; DOXORUBICIN; FEMALE; HUMANS; IODIZED OIL; LIVER NEOPLASMS; MALE; MICROSPHERES; MIDDLE AGED; STARCH;

EID: 34250358606     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-156.
2. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127 (Suppl 1):S5-S16.
3. Kubicka S, Rudolph KL, Hanke M, Tietze MK, Tillmann HL, Trautwein C, et al. Hepatocellular carcinoma in Germany: a retrospective epidemiological study from a low-endemic area. Liver 2000;20:312-318.
4. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236.
5. Bartolozzi C, Lencioni R, Caramella D, Vignali C, Cioni R, Mazzeo S, et al. Treatment of large HCC: transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization. Radiology 1995;197:812-818.
6. Mathurin P, Rixe O, Carbonell N, Bernard B, Cluzel P, Bellin MF, et al. Review article: Overview of medical treatments in unresectable hepatocellular carcinoma--an impossible meta-analysis? Aliment Pharmacol Ther 1998; 12:111-126.
7. Simonetti RG, Liberati A, Angiolini C, Pagliaro L. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol 1997;8: 117-136.
8. Giorgio A, Tarantino L, de Stefano G, Scala V, Liorre G, Scarano F, et al. Percutaneous sonographically guided saline-enhanced radiofrequency ablation of hepatocellular carcinoma. AJR Am J Roentgenol 2003;181:479-484.
9. Rhim H, Dodd GD 3rd, Chintapalli KN, Wood BJ, Dupuy DE, Hvizda JL, et al. Radiofrequency thermal ablation of abdominal tumors: lessons learned from complications. Radiographics 2004;24:41-52.
10. Dettmer A, Kirchhoff TD, Gebel M, Zender L, Malek NP, Panning B, et al. Combination of repeated single-session percutaneous ethanol injection and transarterial chemoembolisation compared to repeated single-session percutaneous ethanol injection in patients with non-resectable hepatocellular carcinoma. World J Gastroenterol 2006;12:3707-3715.
11. Poon RT, Ngan H, Lo CM, Liu CL, Fan ST, Wong J. Transarterial chemoembolization for inoperable hepatocellular carcinoma and postresection intrahepatic recurrence. J Surg Oncol 2000;73:109-114.
12. Tancredi T, McCuskey PA, Kan Z, Wallace S. Changes in rat liver microcirculation after experimental hepatic arterial embolization: comparison of different embolic agents. Radiology 1999;211:177-181.
13. Raoul JL, Heresbach D, Bretagne JF, Ferrer DB, Duvauferrier R, Bourguet P, et al. Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. Cancer 1992;70:585-590.
14. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-1739.
15. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164-1171.
16. Llovet M, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37:429-442.
17. Llad inverted question marko L, Virgili J, Figueras J, Valls C, Dominguez J, Rafecas A, et al. A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. Cancer 2000;88:50-57.
18. No authors listed. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. N Engl J Med 1995;332:1256-1261.
19. Chan AO, Yuen MF, Hui CK, Tso WK, Lai CL. A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer 2002;94: 1747-1752.
20. Taniguchi K, Nakata K, Kato Y, Sato Y, Hamasaki K, Tsuruta S, et al. Treatment of hepatocellular carcinoma with transcatheter arterial embolization. Analysis of prognostic factors. Cancer 1994;73:1341-1345.
21. Lindell B, Aronsen KF, Nosslin B, Rothman U. Studies in pharmacokinetics and tolerance of substances temporarily retained in the liver by microsphere embolization. Ann Surg 1978;187:95-99.
22. Dakhil S, Ensminger W, Cho K, Niederhuber J, Doan K, Wheeler R. Improved regional selectivity of hepatic arterial BCNU with degradable microspheres. Cancer 1982;50:631-635.
23. Taguchi T. Chemo-occlusion for the treatment of liver cancer. A new technique using degradable starch microspheres. Clin Pharmacokinet 1994;26:275-291.
24. Hakansson L, Hakansson A, Morales O, Thorelius L, Warfving T. Spherex (degradable starch microspheres) chemo-occlusion--enhancement of tumor drug concentration and therapeutic efficacy: an overview. Semin Oncol 1997;24 (Supp16):S6-100-S6-109.
25. Furuse J, Ishii H, Satake M, Onaya H, Nose H, Mikami S, et al. Pilot study of transcatheter arterial chemoembolization with degradable starch microspheres in patients with hepatocellular carcinoma. Am J Clin Oncol 2003;26:159-164.
26. Kirchhoff TD, Rudolph KL, Layer G, Chavan A, Greten TF, Rosenthal H, et al. Chemoocclusion vs. chemoperfusion for treatment of advanced hepatocellular carcinoma: a randomised trial. Eur J Surg Oncol 2006;32:201-207.
27. Kanematsu T, Inokuchi K, Sugimachi K, Furuta T, Sonoda T, Tamura S, et al. Selective effects of lipiodolized antitumor agents. J Surg Oncol 1984;25:218-226.
28. Takayasu K, Shima Y, Muramatsu Y, Moriyama N, Yamada T, Makuuchi M, et al. Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents. Radiology 1987;163:345-351.
29. Kan Z, Sato M, Ivancef K, Uchida B, Hedgpeth P, Luderquist A, et al. Distribution and effect of iodized poppyseed oil in the liver after hepatic artery embolization: experimental study in several animal species. Radiology 1993;186:861-866.
30. Greten TF, Papendorf F, Bleck JS, Kirchhoff T, Wohlberedt T, Kubicka S, et al. Survival rate in patients with hepatocellular carcinoma: a retrospective analysis. Br J Cancer 2005;92:1862-1868.
31. Civalleri D, Pector JC, Hakansson L, Arnaud JP, Duez N, Buyse M. Treatment of patients with liver metastases from colorectal cancer by chemo-occlusion with degradable starch microspheres. Br J Surg 1994;81:1338-1341.
32. Carr BI, Zajko A, Bron K, Orons P, Sammon J, Baron R. Phase II study of Spherex (degradable starch microspheres) injected into the hepatic artery in conjunction with doxorubicin and cisplatin in the treatment of advanced-stage hepatocellular carcinoma: interim analysis. Semin Oncol 1997; 24 (Suppl 6):S6-97-S6-99.
33. Johansson CJ. Pharmacokinetic rationale for chemotherapeutic drugs combined with intra-arterial degradable starch microspheres (Spherex). Clin Pharmacokin 1996;31:231-240.
34. Vogl TJ, Trapp M, Schroeder H, Mack M, Schuster A, Schmitt J, et al. Transarterial chemoembolization for hepatocellular carcinoma: volumetric and morphologic CT criteria for assessment of prognosis and therapeutic success-results from a liver transplantation center. Radiology 2000;214:349-357.
35. Savastano S, Miotto D, Casarrubea G, Teso S, Chiesura-Corona M, Feltrin GP. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with Child's grade A or B cirrhosis: a multivariate analysis of prognostic factors. J Clin Gastroenterol 1999; 28:334-340.
36. Cammà C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002;224:47-54.
37. Katyal S, Oliver JH, Peterson MS, Chang PJ, Baron RL, Carr BI. Prognostic significance of arterial phase CT for prediction of response to transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma: a retrospective analysis. AJR Am J Roentgenol 2000;175:1665-1672.
38. Takayasu K, Muramatsu Y, Maeda T, Iwata R, Furukawa H, Muramatsu Y, et al. Targeted transarterial oily chemoembolization for small foci of hepatocellular carcinoma using a unified helical CT and angiography system: analysis of factors affecting local recurrence and survival rates. AJR Am J Roentgenol 2001;176:681-688.
39. Tateishi R, Yoshida H, Shiina S, Imamura H, Hasegawa K, Teratani T, et al. Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. Gut 2005;54:419-425.